Clinical trial
A Study of rhBMP-2/CPM in Closed Fractures of the Humerus
NCT00384852 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00384852 |
|---|---|
| Title | A Study of rhBMP-2/CPM in Closed Fractures of the Humerus |
| Official title | A Phase 2, Multicenter, Double-Blind, Randomized, Stratified, Controlled, Efficacy, Safety and Feasibility Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) as an Adjuvant Therapy in Closed Fractures of the Humerus |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fractures |
| Intervention type | Drug |
| Interventions | rhBMP-2/CPM |
| Enrollment | 139 |
| Start date | Jan 1, 2007 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | Oct 6, 2006 |
| Last update posted | Feb 28, 2013 |
| Countries | Australia, Brazil, Canada, Finland, France, Germany, Mexico, Norway, Romania, Sweden, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: